Clinical and biochemical features of different molecular etiologies of familial chylomicronemia
Key result
Non-LPL-FCS shows higher postheparin LPL activity and LDL cholesterol compared to LPL-FCS.
- n=52
Population
52 individuals with Familial chylomicronemia syndrome enrolled in a phase 3 randomized placebo-controlled…
Design
Cross-sectional
Authors
Discussion
Loading...
Member takes
Implication
Similar FCS phenotypes despite LPL differences support cautious subtyping; leaves open genotype-specific outcomes in prospective studies.
Study Design
Type
RCT (n=52)
Blinding
Placebo-controlled
Randomization
Randomized
Structured PICO
P
Population
52 individuals with familial chylomicronemia syndrome participating in a phase 3 trial, evaluated for baseline clinical and metabolic phenotypes.
O
Outcome
Baseline clinical, fasting, and postfat load metabolic markerssurrogate
LPL-FCS and non-LPL-FCS patients share largely similar phenotypes with extremely high triglycerides, though non-LPL-FCS patients exhibit higher postheparin LPL activity and LDL cholesterol.
Cite This Study
Hegele et al. (2018) conducted an RCT in Familial chylomicronemia syndrome (n=52). Volanesorsen vs. Placebo was evaluated on Baseline clinical, fasting, and postfat load metabolic markers. Among 52 patients with familial chylomicronemia syndrome, non-LPL-FCS individuals had significantly higher postheparin LPL activity and LDL cholesterol compared to LPL-FCS individuals.